$DMTKQ
DermTech Inc

2021 Q2 Form 10-Q Financial Statement

#000156459021040918 Filed on August 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $3.119M $844.0K
YoY Change 269.55% 37.46%
Cost Of Revenue $2.624M $1.445M
YoY Change 81.59%
Gross Profit $495.0K -$601.0K
YoY Change -182.36% 734.72%
Gross Profit Margin 15.87% -71.21%
Selling, General & Admin $14.21M $7.962M
YoY Change 78.45% 190.8%
% of Gross Profit 2870.3%
Research & Development $3.594M $864.0K
YoY Change 315.97%
% of Gross Profit 726.06%
Depreciation & Amortization $200.0K $100.0K
YoY Change 100.0% 0.0%
% of Gross Profit 40.4%
Operating Expenses $17.80M $8.826M
YoY Change 101.7% 171.07%
Operating Profit -$17.31M -$9.427M
YoY Change 83.59% 183.26%
Interest Expense $35.00K $10.00K
YoY Change 250.0% -103.09%
% of Operating Profit
Other Income/Expense, Net $205.0K -$170.0K
YoY Change -220.59% 325.0%
Pretax Income -$17.10M -$9.420M
YoY Change 81.55% 6628.57%
Income Tax
% Of Pretax Income
Net Earnings -$17.10M -$9.597M
YoY Change 78.2% 159.94%
Net Earnings / Revenue -548.32% -1137.09%
Basic Earnings Per Share -$0.59
Diluted Earnings Per Share -$0.59 -$583.3K
COMMON SHARES
Basic Shares Outstanding 28.98M shares
Diluted Shares Outstanding 28.98M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $268.3M $61.10M
YoY Change 339.04%
Cash & Equivalents $229.6M $61.10M
Short-Term Investments $38.64M
Other Short-Term Assets $134.0K $50.00K
YoY Change 168.0%
Inventory $497.0K $100.0K
Prepaid Expenses
Receivables $2.185M $700.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $272.2M $62.50M
YoY Change 335.6% 102305.3%
LONG-TERM ASSETS
Property, Plant & Equipment $3.285M $2.100M
YoY Change 56.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $167.0K $200.0K
YoY Change -16.5%
Total Long-Term Assets $3.452M $2.200M
YoY Change 56.91% -82.3%
TOTAL ASSETS
Total Short-Term Assets $272.2M $62.50M
Total Long-Term Assets $3.452M $2.200M
Total Assets $275.7M $64.70M
YoY Change 326.12% 417.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.104M $800.0K
YoY Change 163.0% -66.67%
Accrued Expenses $887.0K $2.600M
YoY Change -65.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $112.0K
YoY Change
Total Short-Term Liabilities $7.642M $5.800M
YoY Change 31.76% 134.9%
LONG-TERM LIABILITIES
Long-Term Debt $170.0K $0.00
YoY Change
Other Long-Term Liabilities $579.0K
YoY Change
Total Long-Term Liabilities $749.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.642M $5.800M
Total Long-Term Liabilities $749.0K $0.00
Total Liabilities $8.391M $6.466M
YoY Change 29.77% -4.65%
SHAREHOLDERS EQUITY
Retained Earnings -$160.2M -$108.0M
YoY Change 48.27% -6611.63%
Common Stock $427.5M $166.3M
YoY Change 157.12% 4877.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $267.3M $58.22M
YoY Change
Total Liabilities & Shareholders Equity $275.7M $64.69M
YoY Change 326.19% 417.81%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$17.10M -$9.597M
YoY Change 78.2% 159.94%
Depreciation, Depletion And Amortization $200.0K $100.0K
YoY Change 100.0% 0.0%
Cash From Operating Activities -$12.81M -$6.380M
YoY Change 100.74% 24720.07%
INVESTING ACTIVITIES
Capital Expenditures -$934.0K -$1.020M
YoY Change -8.43%
Acquisitions
YoY Change
Other Investing Activities $751.0K
YoY Change
Cash From Investing Activities -$173.0K -$1.020M
YoY Change -83.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 24.00M 590.0K
YoY Change 3967.97% 5519.05%
NET CHANGE
Cash From Operating Activities -12.81M -6.380M
Cash From Investing Activities -173.0K -1.020M
Cash From Financing Activities 24.00M 590.0K
Net Change In Cash 11.02M -6.810M
YoY Change -261.84% 44687.9%
FREE CASH FLOW
Cash From Operating Activities -$12.81M -$6.380M
Capital Expenditures -$934.0K -$1.020M
Free Cash Flow -$11.87M -$5.360M
YoY Change 121.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160199000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-128029000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
267309000
CY2019Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.5
CY2020Q2 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2020Q2 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2019Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.5
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
427503000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
189868000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3119000
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
844000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5643000
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
1445000
us-gaap Cost Of Revenue
CostOfRevenue
4626000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
639000
CY2021Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
170000
CY2021Q2 us-gaap Liabilities
Liabilities
8391000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
61840000
CY2021Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
112000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2075000
CY2021Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
577000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
226000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
167000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
275700000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
69780000
CY2020Q4 us-gaap Assets
Assets
69780000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
763000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1573000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
905000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
109000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7642000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5425000
CY2020Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1650000
CY2021Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2000
CY2020Q4 us-gaap Liabilities
Liabilities
7940000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29607394
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29607394
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20740413
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20740413
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-9597000
us-gaap Operating Expenses
OperatingExpenses
31737000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9427000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
864000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5845000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-9597000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11861000
CY2020Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
180000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1519000
CY2020Q2 us-gaap Gross Profit
GrossProfit
-601000
us-gaap Gross Profit
GrossProfit
1017000
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3433000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14419000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4529000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11473000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
8826000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30720000
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-170000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-170000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1450000
us-gaap Net Income Loss
NetIncomeLoss
-32170000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16149496
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28070539
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17102000
us-gaap Net Income Loss
NetIncomeLoss
-32170000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17108000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9597000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32167000
CY2020Q1 dmtk Adjustments To Additional Paid In Capital Issuance Of Series B1 Convertible Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIssuanceOfSeriesB1ConvertiblePreferredStock
30971000
CY2020Q1 dmtk Adjustments To Additional Paid In Capital Issuance Of Series B2 Convertible Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIssuanceOfSeriesB2ConvertiblePreferredStock
5071000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
253000
CY2020Q1 dmtk Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
11000
CY2020Q1 dmtk Adjustments To Additional Paid In Capital Issuance Cost Related To Registration
AdjustmentsToAdditionalPaidInCapitalIssuanceCostRelatedToRegistration
-77000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1022000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6897000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
66106000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
205361000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
45728000
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1000
CY2020Q2 dmtk Stock Issued During Period Value Stock Options Exercised And Rsu Release
StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease
123000
CY2020Q2 dmtk Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
471000
CY2020Q2 dmtk Adjustments To Additional Paid In Capital Issuance Cost Related To Registration
AdjustmentsToAdditionalPaidInCapitalIssuanceCostRelatedToRegistration
-5000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1125000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-9597000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
58224000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
61840000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
134582000
CY2021Q1 dmtk Stock Issued During Period Value Stock Options Exercised And Rsu Release
StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease
408000
CY2021Q1 dmtk Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
72081000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
392000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2172000
CY2021Q1 dmtk Reclassification Of Warrant Liability Due To Private Spac Warrants Not Held By Original Holder
ReclassificationOfWarrantLiabilityDueToPrivateSPACWarrantsNotHeldByOriginalHolder
411000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15068000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
256827000
CY2021Q2 dmtk Stock Issued During Period Value Stock Options Exercised And Rsu Release
StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease
188000
CY2021Q2 dmtk Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
5000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3538000
CY2021Q2 dmtk Reclassification Of Warrant Liability Due To Private Spac Warrants Not Held By Original Holder
ReclassificationOfWarrantLiabilityDueToPrivateSPACWarrantsNotHeldByOriginalHolder
23000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17102000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
267309000
us-gaap Profit Loss
ProfitLoss
-32170000
us-gaap Profit Loss
ProfitLoss
-16494000
us-gaap Depreciation
Depreciation
401000
us-gaap Depreciation
Depreciation
148000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1519000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
76000
us-gaap Share Based Compensation
ShareBasedCompensation
5710000
us-gaap Share Based Compensation
ShareBasedCompensation
2147000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-337000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-13000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
705000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
42000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
393000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
48000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-152000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-432000
dmtk Increase Decrease In Accounts Payable And Accrued Compensation
IncreaseDecreaseInAccountsPayableAndAccruedCompensation
1599000
dmtk Increase Decrease In Accounts Payable And Accrued Compensation
IncreaseDecreaseInAccountsPayableAndAccruedCompensation
-712000
dmtk Increase Decrease In Accrued Liabilities And Deferred Revenue
IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue
10000
dmtk Increase Decrease In Accrued Liabilities And Deferred Revenue
IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue
713000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23527000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13780000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
4899000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5450000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
944000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1201000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-393000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1201000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
77000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
69928000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
482000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
596000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24248000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15374000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
229609000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
61102000
us-gaap Interest Paid Net
InterestPaidNet
8000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
24000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
39000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
376000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
392000
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
53000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
229281000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60709000
dmtk Reclassification Of Warrant Liability Due To Private Spac Warrants Not Held By Original Holder
ReclassificationOfWarrantLiabilityDueToPrivateSPACWarrantsNotHeldByOriginalHolder
434000
dmtk Cashless Exercise Of Common Stock Warrants
CashlessExerciseOfCommonStockWarrants
2158000
dmtk Change In Unrealized Gain Loss On Available For Sale Marketable Securities
ChangeInUnrealizedGainLossOnAvailableForSaleMarketableSecurities
3000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-two 
CY2019Q4 dmtk Warrant Liability Non Current
WarrantLiabilityNonCurrent
628000
CY2019Q4 us-gaap Liabilities
Liabilities
6350000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
103412000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91552000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11861000
CY2020Q2 dmtk Warrant Liability Non Current
WarrantLiabilityNonCurrent
704000
CY2020Q2 us-gaap Liabilities
Liabilities
6466000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
166268000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108046000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
58224000
CY2020Q4 dmtk Warrant Liability Non Current
WarrantLiabilityNonCurrent
1650000
CY2020Q4 us-gaap Liabilities
Liabilities
7940000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
189868000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-128029000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
61840000
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
441000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1228000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2525000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1188000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-20130000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-36477000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.87
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.15
CY2020Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
180000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
76000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-170000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-66000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-9597000
us-gaap Net Income Loss
NetIncomeLoss
-16494000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.13
dmtk Net Change In Net Cash Used In Operating Activities
NetChangeInNetCashUsedInOperatingActivities
0
us-gaap Use Of Estimates
UseOfEstimates
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.04%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">d</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Use of Estimates </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.3%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to those related to assay revenue, stock-based compensation, short-term marketable securities, accounts receivable, accrued bonus, warrant liability and the realization of deferred tax assets. Actual results may differ from those estimates. </p>
CY2021Q2 us-gaap Depreciation
Depreciation
200000
CY2020Q2 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
100000
CY2021Q2 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
100000
us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2021Q2 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">i</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Concentration of Credit Risk </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.25%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. As of June 30, 2021, the Company maintained $100.0 million in a sweep account, which maintains cash balances throughout various interest bearing bank accounts under the $250,000 insurance limit provided by the Federal Deposit Insurance Corporation for one federally insured financial institution. Approximately $129.3 million was held in excess of the Federal Deposit Insurance Corporation insured limit as of June 30, 2021. The Company has not experienced any losses in such accounts. </p>
CY2021Q2 us-gaap Deposits Money Market Deposits
DepositsMoneyMarketDeposits
100000000.0
CY2021Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2021Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
129300000
dmtk Number Of Revenue Streams
NumberOfRevenueStreams
2
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3119000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
844000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5643000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2401000
CY2021Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1400000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
900000
CY2021Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
600000
CY2021Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
500000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3500000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5700000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2100000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
34800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
38642000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
9000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
38644000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
39530000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
8000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
39529000
CY2021Q2 dmtk Estimated Market Value Of Debt Securities With Contractual Maturities Of Less Than12 Months
EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months
36900000
CY2021Q2 dmtk Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To14 Months
EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo14Months
1800000
CY2020Q4 dmtk Estimated Market Value Of Debt Securities With Contractual Maturities Of Less Than12 Months
EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months
37300000
CY2020Q4 dmtk Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To14 Months
EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo14Months
2300000
CY2021Q2 us-gaap Prepaid Insurance
PrepaidInsurance
376000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1172000
CY2021Q2 dmtk Prepaid Trade Shows Current
PrepaidTradeShowsCurrent
43000
CY2021Q2 dmtk Prepaid Software Fees
PrepaidSoftwareFees
760000
CY2020Q4 dmtk Prepaid Software Fees
PrepaidSoftwareFees
214000
CY2020Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
56000
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
134000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
79000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1313000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1521000
CY2021Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
3404000
CY2020Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2544000
CY2021Q2 dmtk Computer Equipment Gross
ComputerEquipmentGross
97000
CY2020Q4 dmtk Computer Equipment Gross
ComputerEquipmentGross
38000
CY2021Q2 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
92000
CY2020Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
109000
CY2021Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
727000
CY2020Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
727000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4320000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3418000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1035000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
687000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3285000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2731000
CY2021Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
905000
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
606000
CY2021Q2 dmtk Accrued Bonus And Deferred Compensation Current
AccruedBonusAndDeferredCompensationCurrent
2262000
CY2020Q4 dmtk Accrued Bonus And Deferred Compensation Current
AccruedBonusAndDeferredCompensationCurrent
1469000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3167000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2075000
CY2021Q2 dmtk Accrued Consulting Services Current
AccruedConsultingServicesCurrent
254000
CY2020Q4 dmtk Accrued Consulting Services Current
AccruedConsultingServicesCurrent
285000
CY2021Q2 us-gaap Deferred Rent Credit
DeferredRentCredit
254000
CY2020Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
300000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
379000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
178000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
887000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
763000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
615385
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4237288
CY2021Q1 dmtk Stock Purchased By Underwriters Pursuant To Option Granted
StockPurchasedByUnderwritersPursuantToOptionGranted
635593
CY2021Q1 dmtk Underwriters Grant Period Option
UnderwritersGrantPeriodOption
P30D
CY2021Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
4872881
CY2021Q1 dmtk Stock Purchased By Underwriters Pursuant To Option Granted
StockPurchasedByUnderwritersPursuantToOptionGranted
635593
CY2021Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
29.50
CY2021Q1 dmtk Gross Proceeds From Offering Before Deducting Underwriting Discounts And Commissions And Other Offering Expenses
GrossProceedsFromOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses
143700000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
134600000
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4757
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7332
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q2 dmtk Interest Rate Implicit In Lease Arrangement
InterestRateImplicitInLeaseArrangement
0.0554
CY2021Q2 us-gaap Capital Leases Future Minimum Payments Net Minimum Payments1
CapitalLeasesFutureMinimumPaymentsNetMinimumPayments1
301000
CY2020Q4 us-gaap Capital Leases Future Minimum Payments Net Minimum Payments1
CapitalLeasesFutureMinimumPaymentsNetMinimumPayments1
362000
CY2021Q2 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
19000
CY2020Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
27000
CY2021Q2 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
282000
CY2020Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
335000
CY2021Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
112000
CY2020Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
109000
CY2021Q2 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
170000
CY2020Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
226000
us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
In January 2013, DermTech Operations entered into a non-cancelable lease agreement for its operating facilities. In January 2014, DermTech Operations signed an amendment to the lease to extend the term through January 2017. In November 2016, DermTech Operations signed a second amendment to the lease to extend the term through March 2022. In August 2019, DermTech Operations signed a third amendment to the lease to add additional space, and in September 2019, the Company signed a fourth amendment to the lease to add additional space. In February 2020, the Company signed a fifth amendment to the lease to add additional space. In connection with the Business Combination, the Company assumed all obligations under the lease, as amended, from DermTech Operations.
CY2021Q2 dmtk Tenant Improvement Allowance
TenantImprovementAllowance
300000
CY2021Q2 dmtk Real Estate Rent And Common Area Maintenance Expense
RealEstateRentAndCommonAreaMaintenanceExpense
500000
CY2020Q2 dmtk Real Estate Rent And Common Area Maintenance Expense
RealEstateRentAndCommonAreaMaintenanceExpense
600000
dmtk Real Estate Rent And Common Area Maintenance Expense
RealEstateRentAndCommonAreaMaintenanceExpense
1000000.0
dmtk Real Estate Rent And Common Area Maintenance Expense
RealEstateRentAndCommonAreaMaintenanceExpense
800000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
690000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1411000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
478000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2579000
CY2021Q2 dmtk Operating And Capital Lease Liability Payments Remainder Of Fiscal Year
OperatingAndCapitalLeaseLiabilityPaymentsRemainderOfFiscalYear
753000
CY2021Q2 dmtk Operating And Capital Lease Liability Payments Due Next Twelve Months
OperatingAndCapitalLeaseLiabilityPaymentsDueNextTwelveMonths
1535000
CY2021Q2 dmtk Operating And Capital Lease Liability Payments Due Year Two
OperatingAndCapitalLeaseLiabilityPaymentsDueYearTwo
592000
CY2021Q2 dmtk Operating And Capital Lease Liability Payments Due
OperatingAndCapitalLeaseLiabilityPaymentsDue
2880000
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
0
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
0

Files In Submission

Name View Source Status
0001564590-21-040918-index-headers.html Edgar Link pending
0001564590-21-040918-index.html Edgar Link pending
0001564590-21-040918.txt Edgar Link pending
0001564590-21-040918-xbrl.zip Edgar Link pending
dmtk-10q_20210630.htm Edgar Link pending
dmtk-10q_20210630_htm.xml Edgar Link completed
dmtk-20210630.xsd Edgar Link pending
dmtk-20210630_cal.xml Edgar Link unprocessable
dmtk-20210630_def.xml Edgar Link unprocessable
dmtk-20210630_lab.xml Edgar Link unprocessable
dmtk-20210630_pre.xml Edgar Link unprocessable
dmtk-ex311_10.htm Edgar Link pending
dmtk-ex312_8.htm Edgar Link pending
dmtk-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending